Curing people.
Healing lives.

Improving access to biosimilars
for patients across the globe.

LEARN MORE

Delivering high quality
biosimilars

Transforming healthcare
through affordable therapies.

LEARN MORE

Driving biosimilar development
from Gene to GMP

Nurturing deep development capabilities &
world class manufacturing infrastructure.

LEARN MORE

WHO WE ARE

Our Vision

Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them with an access to high quality and cost-effective biosimilars.

Our Mission

Deliver exceptional value to stakeholders and better health outcomes to patients by becoming a leading global biosimilars developer by 2030.

Build deep capabilities in development and manufacturing to deliver quality and cost-effective biosimilars for patients across the globe.

Create a sustainable and broad portfolio of biosimilars with a focus on oncology and immunology therapies.

Biosimilar medicines patient 1
Biosimilar medicines patient 2
Biosimilar medicines patient 3
Biosimilar medicines patient 4
Biosimilar medicines patient 5
CuratTeQ Biologics strategy Image background

OUR STRATEGY

Business Strategy

Our biosimilars business strategy is built around the following five core themes:

  1. Focus on Oncology and Immunology segments
  2. Invest in deep development capabilities and in-house manufacturing
  3. Commercialise in EU and EMs, with select products for the US markets
  4. Deliver sustainable growth and create long term value through a carefully selected product pipeline
  5. Provide clinical and economic benefit to patients through affordable and high quality biosimilars
Biosimilar medicines regulation

OUR STRATEGY

Regulatory Strategy

Most regulatory authorities are working towards a standard framework for biosimilars development as more evidence about their safety and efficacy is becoming available.

The need for efficacy trials to the subject of interchangeability are being debated as new regulatory guidelines become available.

Biosimilar medicines strategy

Wherever possible, CuraTeQ has strategically adopted an abridged licensure approach to push the time-to-market barriers and shorten product development timelines by:

  • Demonstrating analytical biosimilarity and PK/PD comparability vis-a-vis the reference product
  • Having early engagement with regulatory agencies (US FDA, EMA, MHRA etc.) to obtain the necessary buy-ins about Phase 3 clinical study requirements
  • Leveraging feedback from regulatory agencies to address any “residual uncertainty” based on the evidence of analytical biosimilarity and clinical pharmacology assessment

We believe to the extent possible, efficacy trials in patients may not be always necessary provided biosimilarity can be proven through a thorough analytical assessment and PK/PD studies.

Having said that, CuraTeQ Biologics believes in constructively engaging with the regulatory agencies and doing what is necessary to bring these life saving biosimilars to the patients across the globe.

As on date, CuraTeQ Biologics has filed three biosimilars with regulatory agencies based on analytical biosimilarity and PK/PD data, while we are also conducting Phase 3 clinical studies for three of our other products.

What are Biosimilars?

US FDA

As per US FDA, a biosimilar is a biological product that is highly similar to the reference product notwithstanding minor differences in clinically inactive components and has no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency of the product.1

MHRA

As per MHRA, a biosimilar is a biological medicinal product that contains a version of the active substance of an already authorised original biological medicinal product i.e. the reference product (RP). A biosimilar should be highly similar to the RP in physicochemical properties, biological activity/potency and clinical profiles.2

EMA

As per EMA, a biosimilar is a biological medicine highly similar to another already approved biological medicine (the ‘reference medicine’). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicine.3

CDSCO

As per CDSCO, a biosimilar is a biological product which is similar in terms of quality, safety, and efficacy to reference biological product licensed or approved in India based on comparability, or any innovator product approved in International Council of Harmonisation (ICH) member countries.4

References:

  1. US FDA: Section 351(k) of the PHS ACT (42 U.S.C. 262(k)), 2010.
  2. MHRA: Guidance on the Licensing of Biosimilar Products, 2022.
  3. EMA: Guideline on Similar Biological Medicinal Products, CHMP/437/04 Rev 1, 2015.
  4. DBT-CDSCO: Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorisation in India, 2016.

Evolving Paradigm for Biosimilars1

Reference Product

Current Biosimilar Product

Future Biosimilar Product

References:
1. Adapted from “BsUFA III Regulatory Research Pilot Program: Research Roadmap, 2023

OUR CAPABILITIES

Development Capabilities

The CuraTeQ Biologics R&D Centre has a footprint of 33,000 sq. ft and employs more than 125 scientists.

A number of PhDs are involved in developing our portfolio of biosimilars.

Key features of our R&D capabilities:

Cell line development

curateq-biologics icon 2

Fermentation sciences

Mammalian cell culture

curateq-biologics icon

Protein purification

Process characterisation

curateq-biologics icon

Analytical product characterisation

curateq-biologics icon

Formulations

curateq-biologics icon

Cell based functional assays

curateq-biologics icon

Clinical immunology

curateq biologics icon

Scale down and scale up

OUR CAPABILITIES

cGMP Capabilities

Our biosimilars manufacturing centre in Hyderabad, India, is a fully integrated commercial scale facility.

It has end-to-end capabilities in producing a full range of products from bulk drug substance (DS) to fill-finish and packaged drug products (DP).

Biosimilar medicines manufacturing

Key features of our cGMP facilities:

Biosimilar medicines icon 1

140,000 sq. ft. multi product manufacturing facility

curateq-biologics icon 2

Mammalian Drug Substance manufacturing section housing four 2500 L scale SS bioreactors

Biosimilar medicines icon 3

Microbial Drug Substance manufacturing section housing two 250 L scale SS bioreactors

Biosimilar medicines icon 4

Segregated filling sections for Vials and Pre-filled syringes/cartridges

Biosimilar medicines icon 5

Systems designed as per 21 CFR Part 11, and GAMP 5 ISPE guidelines

Biosimilar medicines icon 6

QC testing laboratories for products lot release, raw material, packaging material, microbiology and sterility testing

Biosimilar medicines icon 7

Centrally located warehouse for ease of servicing various manufacturing sections

Biosimilar medicines icon 8

Designed for optimal man and material movement to mitigate cross contamination

Biosimilar medicines icon 9

Designed for automated Clean-In-Place (CIP) and Sterilisation-In-Place (SIP) operations

Biosimilar medicines icon 10

Automated buffer distribution and handling capabilities

Biosimilar medicines icon 11

Continuous monitoring through Building Management Systems (BMS)

Biosimilar medicines icon 12

Water for Injection (WFI) generation facility with cold and hot loops

Latest News

CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar
Press Release

15 March 24

CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar

Read More
Auro Peptides completes US FDA inspection with zero observations
Press Release

17 February 24

Auro Peptides completes US FDA inspection with zero observations

Read More
CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India
Press Release

17 January 24

CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India

Read More
CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector
Press Release

20 November 23

CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector

Read More
CuraTeQ Biologics to market Ustekinumab biosimilar to treat Crohn’s disease, arthritis
Press Release

10 July 23

CuraTeQ Biologics to market Ustekinumab biosimilar to treat Crohn’s disease, arthritis

Read More
CuraTeQ Biologics announces positive Phase-3 results for Trastuzumab biosimilar
Press Release

05 July 23

CuraTeQ Biologics announces positive Phase-3 results for Trastuzumab biosimilar

Read More
Aurobindo Pharma arm CuraTeQ expands scope of biosimilars distribution pact with Orion
Press Release

12 January 22

Aurobindo Pharma arm CuraTeQ expands scope of biosimilars distribution pact with Orion

Aurobindo Pharma on Tuesday said its subsidiary CuraTeQ Biologics has expanded the scope…

Read More
Aurobindo Pharma forays into biosimilars development
Press Release

12 February 17

Aurobindo Pharma forays into biosimilars development

Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar…

Read More